All of the content is original - a movie we made, making of videos about that movie and other original shorts. So we have no idea what you are flagging as reused. The appeal video I sent (according to your analytics) has 1 view and was watched for 0.1 seconds.
@TeamYouTube: Our original film channel was flagged for reused content. My appeal was rejected. I have proof of ownership/originality (Project files, raw footage). Can anyone help a small content creator (new to X). Pretty please? @PhillyD @PRO_YouTube @YouTubeCreators
Is this a Guinness world record attempt for rambling idiocy. If so someone tell him to shut the F*ck up, he got it about 30 minutes ago. #TrumpTariffs#Trump
This is not a Banksy piece. Historically the artist posts his work on his Instagram page. It does not appear there.
The real artist’s name, Loretta, is clearly visible at left.
instagram.com/banksy?igsh=b2…
Is Cambridge University right to enforce a retirement age? I think so – who wants to be a ‘job blocker’? But what are you supposed to do between retiring and dying? Visit the grandkids on your senior railcard???? theguardian.com/commentisfre…
Congratulations to Dr Diarmuid O'Brien @DIOBRIEN1, who has been appointed as the University of Cambridge’s new Pro-Vice-Chancellor for Innovation.
He is currently Chief Executive of @UCamEnterprise, and will take over from current Senior Pro-Vice-Chancellor Prof @AndyNeely.
“I’m delighted that a new chapter in our partnership with @BioNTech_Group features at today’s Global Investment Summit, hosted by UK Prime Minister @RishiSunak@10DowningStreet"
Cambridge Pro-Vice-Chancellor Professor Andy Neely comments on the Global Investment Summit 🔽
ALT “I’m delighted that a new chapter in our partnership with BioNTech features at today’s Global Investment Summit, hosted by UK Prime Minister Rishi Sunak.
BioNTech intends to set up new laboratories in Cambridge with an expected capacity of more than 70 highly skilled scientists, which builds on their existing commitment to help provide up to 10,000 patients with precision cancer immunotherapies by 2030.
We are delighted to host BioNTech in Cambridge.”
Professor Andy Neely, Senior Pro-Vice-Chancellor for Enterprise and Business Relations